期刊文献+

新型抗IL-1β和IL-17A双特异抗体的构建及特性鉴定 被引量:2

Construction and characterization of a novel bispecific antibody against both IL-1β and IL-17A
原文传递
导出
摘要 目的双特异性抗体(bispecific antibody,BsAb)具有双重的生物学功能。本实验旨在设计并原核表达抗人IL-1β和抗人IL-17A的双特异性抗体(BsAb1/17),获得具有生物活性的BsAb1/17,为深入研究和利用双特异性抗体奠定基础。方法利用重叠PCR方法构建VH1VL17-CL和VL1VH17-CH1基因片段,并且在所用引物的5’和3’端附加NcoI和BamHI的酶切位点。将重叠PCR产物进行胶回收后用NcoI/BamHI进行双酶切,酶切产物再次胶回收,将其连接到用NcoI/BamHI消化的pET-27b载体上。将重组质粒pET-27b—VH1VL17-CL(petA)和pET-27b—VLIVH17-CH1(petB)转化到Eco1iRosetta中。SDS—PAGE和Westernb1ot进行鉴定,用rea1—timePCR检测其阻断IL-1β刺激人T细胞表达细胞因子IL-1β的活性,人IL-6定量酶联检测试剂盒检测其阻断IL-17A刺激HeLa细胞表达人IL-6的活性。结果DNA测序结果证明成功构建了pET-27b-VHIVL17-CL(petA)和pET-27b-VL1VH17-CH1(petB)表达质粒。petA、petB诱导产物主要以包涵体形式存在,成熟蛋白纯化产物纯度超过90%以上,经SDS-PAGE分析表明表达产物的相对分子质量约为38×10^3,与理论值相符。Western b1ot和ELISA结果证实双特异抗体BsAb1/17对IL-1β和IL-17A均具有很好的亲和力。通过RT-PCR检测证明其具有阻断IL-1β刺激人T细胞大量表达细胞因子IL-1β的活性,并且具有阻断IL-17A刺激HeLa细胞产生IL-6的活性。结论成功构建了同时抗IL-1β和IL-17A的双特异抗体,并利用大肠杆菌表达系统高效表达较高纯度的具有生物活性的双特异抗体。 [ Abstract ] Objective To construct bispecific antibody BsAb1/17 against both IL-II3 and IL-17A, express and purify the biologically active BsAbl/17 protein in prokaryotic system for further studies and ap- plications. Methods VH1VL17-CL and VL1VH17-CH1 gene segments were constructed by overlap-PCR. Restriction enzyme sites Nco I and BamH I were designed at the 5'and 3' end primers respectively. The products of overlap-PCR were ligated to the Nco I/BamH I -prepared pET-27b vector. The recombinant plasmids pET-27b-VH1VL17-CL(petA) and pET-27b-VL1VH17-CH1 (petB)were transformed into E. coli- Rosetta separately. The expressing products were analyzed by SDS-PAGE and Western blot. Neutralization activity of the bispecific antibody for blocking the induction of IL-18 expression by IL-113 in human T cells was determined by real-time PCR. Neutralization activity of the bispecific antibody for blocking the induction of IL-6 expression by IL-17A in HeLa cells was determined by ELISA assay. Results The structure of the plasmids pET-27b-VH1VL17-CL(petA) and pET-27b-VL1VH17-CH1 (petB) was confirmed by DNA sequen- cing. After induction, the fusion proteins were expressed mainly as inclusion bodies. The purity of the both proteins exceeded 90%. SDS-PAGE analysis suggests the relative molecular mass of both products expressed by petA and petB were approximately 38×10^3, which is in accordance with the theoretical value. The results of Western blot and ELISA test demonstrated that BsAbl/17 molecule had binding ability to both IL-1β and IL-17A. The BsAbl/17 could block IL-1β to stimulate human T cell to express IL-18 and block IL-17A to stimulate HeLa cell to express IL-6. Conclusion We successfully constructed a novel bispecific antibody BsAbl/17 against both IL-1β and IL-17A, and expressed biologically active BsAbl/17 protein in prokaryotic system.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2011年第7期623-629,共7页 Chinese Journal of Microbiology and Immunology
基金 哈尔滨市科技创新人才发展计划(2006RFXXS002) 东北农业大学创新团队发展计划(CXZ001) 黑龙江省博士后科研启动资金(LBH-Q09162) 黑龙江省教育厅项目(11521022) 哈尔滨市科技创新人才研究专项资金(2008RFQXS017,2010RFQXN109) 国家自然科学基金(31001084)
关键词 双特异性抗体 原核表达 Real—time PCR Bispecific antibody Prokaryotic expression Real-time PCR
  • 相关文献

参考文献11

二级参考文献43

  • 1李青,吴雄文,熊敏,翁秀芳,卢小玲,梁智辉,龚非力.BirA酶基因表达载体的构建、原核表达及表达产物的活性鉴定[J].细胞与分子免疫学杂志,2005,21(5):557-560. 被引量:9
  • 2Ya-Ping Zhang Xi-Xian Yao Xia Zhao.Interleukin-1 beta up-regulates tissue inhibitor of matrix metalloproteinase-1 mRNA and phosphorylation of c-jun N-terminal kinase and p38 in hepatic stellate cells[J].World Journal of Gastroenterology,2006,12(9):1392-1396. 被引量:22
  • 3Dinarello CA, Biologic basis for interleukin-1 in disease [ J ]. Blood, 1996, 87(6): 2095-2147. 被引量:1
  • 4Danielle B, Dayer JM, Palmer G, et al. Is IL-I a good therapeutic target in the treatment of arthritis[J]. Best Pract Res Clin Rheumatol, 2006, 20 (5) : 879 - 896. 被引量:1
  • 5Basak C, Pathak S K, Bhattaeharyya A. NF-kappaB-and C/EBP beta-driven interleukin-lbeta gene expression and PAKl-mediated caspase-1 activation flay essential roles in interleukin-1 beta release from Helicobacter pylori lipopolysaccharide-stimulated macrophages [./]. J Biol Chem, 2005, 280(6) : 4279 - 4288. 被引量:1
  • 6Newton R, Holden NS, Catley MC. Repression of inflammatory gene expression in human pulmonary epithelial cells by Small-molecule kappa B kinase inhibitors[J]. J Pharmacol Exp Ther, 2007, 321 (2) : 734 - 742. 被引量:1
  • 7Dinarello CA. Interleukin-1 and interleukin-1 antagonism [J]. Blood, 1991,77(8): 1627- 1652. 被引量:1
  • 8[1]Chin JE, Lin YA. Effects of recombinant human interleukin-1 beta on rabbit articular chondrocytes. Stimulation of prostanoid release and inhibition of cell growth. Arthritis-Rheum, 1988, 31(10): 1290-1296. 被引量:1
  • 9[2]Dibattista JA, Martel-Pelletier J, Wosu LO, et al. Glucocorticoid receptor mediated inhibition of interleukin-1 stimulated neutral metalloprotease synthesis in normal human chondrocytes. J Clin Endocrinol Metab, 1991 , 72(2) :316-326. 被引量:1
  • 10[3]Hulkower KI, Wertheimer SJ, Levin W. Interleukin-1 beta induces cytosolic phospholipase A2 and prostaglandin H synthase in rheumatoid synovial fibroblasts. Evidence for their roles in the production of prostaglandin E2. Arthritis-Rheum, 1994, 37(5):653-661. 被引量:1

共引文献29

同被引文献16

  • 1周茹,杨以阜,左建平.Ⅱ型胶原诱导的小鼠关节炎动物模型的建立及影响因素[J].中国药理学通报,2006,22(12):1532-1535. 被引量:28
  • 2Feldmann M,Maini R N.Anti-TNF-αtherapy of rheumatoid ar-thritis:What have we learned?[J].Annu Rev Immunol,2001,19:163-96. 被引量:1
  • 3Jeong J G,Kim J M,Cho H,et al.Effects of IL-1beta on geneexpression in human rheumatoid synovial broblasts[J].BiochemBiophys Res Commun,2004,324(1):3-7. 被引量:1
  • 4Cohen S,Hurol E,Cush J,et al.Treatment of rheumatoid arthritiswith anakinra,a recombinant human interleukin-1 receptor antago-nist,in combination with methotrexate:results of a twenty-four-week,multicenter,randomized,double-blind,placebocontrolledtrial[J].Arthritis Rheum,2002,46(3):614-24. 被引量:1
  • 5Chabaud M,Miossec P.The combination of tumor necrosis factoralpha blockade with interleukin-1 and interleukin-17 blockade ismore effective for controlling synovial in ammation and bone resorp-tion in an ex vivo model[J].Arthritis Rheum,2001,44(6):1293-303. 被引量:1
  • 6Yao Z,Femslow W C,Seldin M F,et al.Herpesvirus saimiri en-codes a new cytokine,IL-17,which binds to a novel cytokine re-ceptor[J].Immunity,1995,3(6):811-21. 被引量:1
  • 7Lipsky P E,Van der Heijde D M,St Clair E W,et al.Infliximaband methotrexate in the treatment of rheumatoid arthritis.Anti-tumor necrosis factor trial in heumatoid arthritis with concomitanttherapy study group[J].N Engl J Med,2000,343(22):1594-602. 被引量:1
  • 8Cohen S,Hurd E,Cush J,et al.Treatment of rheumatoid arthritiswith anakinra,a recombinant human interleukin-1 receptor antago-nist,in combination with methotrexate:results of a twenty-four-week,multicenter,randomized,double-blind,placebocontrolledtrial[J].Arthritis Rheum,2002,46(3):614-24. 被引量:1
  • 9Ruddy M J,Shen F,Smith J B,et al.Interleukin-17 regulatesexpression of the CXC chemokine LIX/CXCL5 in osteoblasts:im-plications for inflammation and neutrophil recruitment[J].J Leu-koc Biol,2004,76(1):135-44. 被引量:1
  • 10Witowski J,Ksiazek K,Jorres A.Interleukin-17:a mediator ofin?ammatory responses[J].Cell Mol Life Sci,2004,61:567-79. 被引量:1

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部